Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

NCT05897541 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2387

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

DRUG: S-217622
DRUG: Placebo

Sponsor

Shionogi